Your activity: 68 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Approach to insulin therapy for cystic fibrosis-related diabetes

Approach to insulin therapy for cystic fibrosis-related diabetes
Indication Suggested starting doses for insulin 
Patient with high blood glucose on OGTT, or random hyperglycemia with worsening lung function and weight loss

Long-acting (basal) insulin 0.1 units/kg every morning. For patients on glucocorticoids, use starting dose of insulin 0.2 units/kg.

Increase dose by increments of 0.1 units/kg, aiming for postprandial blood glucose <140 mg/dL (7.8 mmol/L), without hypoglycemia.

Hypoglycemia prior to the midday meal when basal insulin is given in the morning, or postprandial blood glucose is in target range, but A1C is high  Split the basal insulin twice per day (two-thirds in morning, one-third in evening) and increase the dose incrementally up to a maximum of 0.5 units/kg.  
Inability to reach glycemic targets on basal insulin alone   Add prandial insulin (0.5 units rapid-acting insulin for each 15 g carbohydrate, given just prior to the meal), in addition to basal insulin.
Hyperglycemia in hospital for infection or pulmonary exacerbation, or patient on glucocorticoids Increase starting dose of basal insulin to 0.2 units/kg. Most patients also require prandial insulin during intercurrent infections.
High blood glucose in patient on overnight enteral feeds Basal insulin 0.1 units/kg at bedtime or combination of short-acting and intermediate-acting insulin.
Difficulties reaching glycemic goals with above regimens, and/or desire for more convenient or physiological insulin replacement Continuous subcutaneous insulin infusion (insulin pump). 
OGTT: oral glucose tolerance test; A1C: hemoglobin A1c (glycated hemoglobin).
Graphic 97532 Version 3.0